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To the Editor—Judith Bosmans et al. [1] present a method for
conducting economic evaluations alongside equivalence and non-
inferiority trials. In analogy to the noninferiority or equivalence
margin for clinical effects, they deﬁne a noninferiority or equiva-
lence margin for costs. In their example trial on patients with
minor depression, they choose a noninferiority margin for clini-
cal effects of -0.03 quality-adjusted life years (QALYs) and a
noninferiority margin for costs of €500. In other words, the new
intervention was considered to be noninferior to the existing
standard if the incremental beneﬁt was no less than -0.03 QALYs
and incremental costs were not higher than €500.
Nevertheless, it is unclear why the noninferiority margin for
costs should be a positive ﬁgure such as €500. An intervention
that is clinically noninferior but leads to higher costs should
not be considered noninferior from an economic viewpoint.
For example, suppose that all bootstrap replications in the cost-
effectiveness plane fall between -0.03 and 0 QALYs as well as
between €0 and €500. In this case, the new intervention is domi-
nated (i.e., considered inferior) by conventional standards, and
it seems questionable to consider such an intervention noninfe-
rior from an economic viewpoint. But even if the noninferiority
margin were close to zero (say, €1), we could not consider an
intervention with costs below this margin economically noninfe-
rior because, in a high-prevalence disease, such as minor depres-
sion population costs may easily add up to millions of Euros.
Only if the noninferiority margin were inﬁnitely small (i.e.,
practically €0), we could safely consider an intervention with
costs below this margin noninferior from an economic view-
point. Therefore, the noninferiority margin for costs should
be 0.—Afschin Gandjour MD, PhD, MA, The James A. Baker III
Institute for Public Policy, Rice University, Houston, TX.
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